Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AVROBIO, Inc. - Common Stock (NQ:AVRO)

1.400 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AVROBIO, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Participate in Four Upcoming Investor Conferences in September
From AVROBIO, Inc.
Via Business Wire
Recap: Avrobio Q2 Earnings
  Avrobio (NASDAQ:AVRO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study
Via Benzinga
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
Via Benzinga
Avrobio: Q1 Earnings Insights
Avrobio (NASDAQ:AVRO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Participate in Two Upcoming Investor Conferences in August
From AVROBIO, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Nanobiotix (NASDAQ:NBTX) shares rose 16.4% to $2.7 during Friday's after-market session. The company's market cap stands at $94.1 million. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Recap: Avrobio Q4 Earnings
Avrobio (NASDAQ:AVRO) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
AVROBIO Shares Climb As FDA Grants Orphan Drug Status To Genetic Disorder Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for AVROBIO’s (NASDAQ: AVRO) lead drug AVR-RD-05 for the treatment of mucopolysaccharidosis type II (MPSII), or Hunter... 
Via Benzinga
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
From AVROBIO, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
From AVROBIO, Inc.
Via Business Wire
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
From AVROBIO
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data
Avrobio Inc's (NASDAQ: AVRO) gene therapy for a rare lysosomal storage disorder  
Via Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 89 companies hit new 52-week lows. Noteable 52-Week Lows: The company with the largest market cap to set a new 52-week low was Seagen (NASDAQ:SGEN).... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.